Shareholders' Equity (Tables)

6 Months Ended

Jun. 30, 2023

Stockholders' Equity Note [Abstract]

Summary of comprehensive income (loss)

The following is a summary of comprehensive income (in millions):

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Consolidated net income	$	57.8		$	49.7		$	135.2		$	111.8
Foreign currency translation adjustments		10.3			(76.9	)		36.1			(107.4	)
Derivatives designated as hedging instruments, net of tax		(15.9	)		41.5			(26.6	)		62.6
Pension liability adjustments, net of tax		0.7			1.6			0.8			2.1
Comprehensive income		52.9			15.9			145.5			69.1
Less: Comprehensive income (loss) attributable to    noncontrolling interests		1.3			(0.4	)		2.6			(0.2	)
Less: Comprehensive loss attributable to redeemable    noncontrolling interests		(0.3	)		(0.5	)		(0.3	)		(0.7	)
Comprehensive income attributable to Bruker Corporation	$	51.9		$	16.8		$	143.2		$	70.0

Summary of the components of accumulated other comprehensive income (loss), net of tax

The following is a summary of the components of accumulated other comprehensive income (loss) attributable to Bruker Corporation, net of tax (in millions):

	Foreign Currency Translation			Derivatives Designated as Hedging Instruments			Pension Liability Adjustment		Accumulated Other Comprehensive Income
Balance at December 31, 2022	$	(3.1	)	$	4.1		$	13.8	$	14.8
Other comprehensive income (loss) before    reclassifications		35.4			(26.6	)		0.3		9.1
Realized gain on amounts reclassified from other comprehensive income		—			—			0.5		0.5
Net current period other comprehensive income (loss)		35.4			(26.6	)		0.8		9.6
Balance at June 30, 2023	$	32.3		$	(22.5	)	$	14.6	$	24.4

Schedule of the impact of stock-based compensation expense

The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (in millions):

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Stock options	$	0.4	$	0.4	$	0.8	$	0.8
Restricted stock units		3.8		3.4		7.5		6.8
Employee Stock Purchase Plan		0.2		—		0.4		—
Total stock-based compensation expense	$	4.4	$	3.8	$	8.7	$	7.6

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Cost of product revenue	$	0.4	$	0.3	$	0.7	$	0.8
Selling, general and administrative		3.5		3.2		7.1		5.9
Research and development		0.5		0.3		0.9		0.9
Total stock-based compensation expense	$	4.4	$	3.8	$	8.7	$	7.6